Treatments aimed at APOE, such as APOE modulators and lipid-lowering drugs, show promise in correcting cholesterol deregulation and decreasing the risk of Alzheimer’s disease, especially among APOE ε4 carriers (Williams et al. 2020). Here, APOE is linked to early-onset autosomal dominant Alzheimer disease.